Top 50 Biotech Startup Investors in Denmark (November 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
36 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
BioInnovation Institute
VC Fund
|
28 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Seed | Biotechnology, Medical, Health Care | $495k–$5.2M |
|
Vaekstfonden
VC Fund
|
21 | Denmark, United States, United Kingdom | Seed, Venture - Series Unknown, Pre-Seed | Software, Information Technology, SaaS | $384k–$23M |
|
Export and Investment Fund
VC Fund
|
20 | Denmark, United States, Norway | Seed, Pre-Seed, Series A | Software, Biotechnology, Health Care | $395k–$84M |
|
Seed Capital
VC Fund
|
11 | Denmark, United States, United Kingdom | Seed, Venture - Series Unknown, Series A | Software, Health Care, Information Technology | $549k–$17M |
|
Sunstone Life Science Ventures
VC Fund
|
7 | Denmark, Sweden, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.1M–$63M |
|
PSV
VC Fund
|
7 | Denmark, United States, Sweden | Seed, Pre-Seed, Venture - Series Unknown | Software, Information Technology, Artificial Intelligence | $307k–$4.6M |
|
Oskare Capital
VC Fund
|
6 | Italy, Denmark, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $1.2M–$5.9M |
|
Nordic Foodtech VC
VC Fund
|
6 | Finland, Denmark, Sweden | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Life Science | $610k–$18M |
|
Gilde Healthcare
VC Fund
|
6 | United States, The Netherlands, Germany | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $9.5M–$135M |
|
The Footprint Firm
VC Fund
|
5 | Denmark, Spain, Norway | Seed, Pre-Seed, Series A | Software, Renewable Energy, Energy Management | $863k–$18M |
|
2xN
VC Fund
|
5 | Denmark, United States, United Kingdom | Seed, Series A, Series B | Software, Information Technology, Quantum Computing | $1.9M–$125M |
|
West Hill Capital
VC Fund
|
5 | United Kingdom, Denmark, Germany | Venture - Series Unknown, Series A, Seed | Health Care, Information Technology, Software | $1.8M–$15M |
|
RA Capital Management
VC Fund
|
5 | United States, United Kingdom, China | Series B, Post-IPO Equity, Series A | Biotechnology, Health Care, Therapeutics | $20M–$275M |
|
DSM Venturing
VC Fund
|
4 | United States, Canada, Israel | Series A, Series B, Venture - Series Unknown | Health Care, Biotechnology, Manufacturing | $2.1M–$48M |
|
Per Falholt
Angel
|
4 | Denmark | Pre-Seed, Series A, Seed | Biotechnology, Robotics, Biopharma | $5.9M–$20M |
|
ACME Capital
VC Fund
|
4 | United States, Denmark, Canada | Seed, Series A, Series B | Software, Health Care, E-Commerce | $1.6M–$65M |
|
PINC
VC Fund
|
4 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Agriculture | $89k–$7.2M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A, Venture - Series Unknown | Software, Biotechnology, Medical Device | $1.2M–$31M |
|
EIR Ventures
VC Fund
|
4 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $20M–$73M |
|
Atlantic
VC Fund
|
4 | Germany, Switzerland, United States | Seed, Pre-Seed, Series A | Software, Health Care, Artificial Intelligence | $850k–$30M |
|
Ysios Capital
VC Fund
|
4 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $3.8M–$135M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $6M–$92M |
|
Nicholas Francis
Angel
|
3 | Denmark, United States | Seed, Series A | SaaS, Robotics, Software | $983k–$8.1M |
|
Blue Horizon Corporation
VC Fund
|
3 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Food and Beverage, Food Processing, Biotechnology | $450k–$40M |
|
Lundbeckfonden Ventures
VC Fund
|
3 | United States, Denmark, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$95M |
|
Karolinska
VC Fund
|
3 | Sweden, Denmark, United States | Venture - Series Unknown, Seed | Biotechnology, Health Care, Pharmaceutical | $2.1M–$10M |
|
Ugly Duckling Ventures
VC Fund
|
3 | Denmark, Sweden, Finland | Seed, Pre-Seed, Venture - Series Unknown | Software, Artificial Intelligence, Information Technology | $917k–$7.5M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Dawn Biopharma
VC Fund
|
3 | United States, Denmark, France | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $15M–$165M |
|
Omega Funds
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Innovation Fund Denmark
VC Fund
|
3 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $38k–$2.1M |
|
Thia Ventures
VC Fund
|
3 | United States, France, Denmark | Series A, Seed, Pre-Seed | Biotechnology, Health Care, Manufacturing | $3.4M–$48M |
|
NOON Ventures
VC Fund
|
3 | Denmark | Seed, Series A | Biotechnology, AgTech, Farming | $4.3M–$8.8M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
Unconventional Ventures
VC Fund
|
3 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Software, Wellness | $1M–$18M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
3 | Germany, Switzerland, United States | Seed, Series A, Venture - Series Unknown | Software, Biotechnology, Health Care | $680k–$31M |
|
SR One
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$175M |
|
Wellcome Trust
VC Fund
|
2 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.6M–$127M |
|
Steen Riisgaard
Angel
|
2 | Denmark | Pre-Seed | Life Science, Therapeutics, Biotechnology | |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
+ND Capital
VC Fund
|
2 | United States, Switzerland, Denmark | Series B, Series C, Series A | Biotechnology, Health Care, Medical | |
|
Innovations Kapital
VC Fund
|
2 | Sweden, Denmark, United States | Series B, Series C | Biotechnology, Health Care, Software | $5.5M–$30M |
|
Bruce Linton
Angel
|
2 | Canada, United States, Denmark | Post-IPO Equity, Seed, Pre-Seed | Cannabis, Health Care, Biotechnology | $40k–$53M |
|
Verve Ventures
VC Fund
|
2 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$45M |
|
Giampaolo Cagnin
Angel
|
2 | Italy, Denmark | Seed, Pre-Seed | Chemical, Biotechnology, Food and Beverage | $4.9M–$7.6M |
|
Northzone
VC Fund
|
2 | United States, Sweden, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, FinTech | $2.4M–$100M |
|
Nordic Alpha Partners
VC Fund
|
2 | Denmark, Germany, Sweden | Venture - Series Unknown, Seed | Energy, Energy Storage, Renewable Energy | $3M–$9.8M |
|
Newtree Impact
VC Fund
|
2 | Denmark | Seed | Biotechnology | |
|
Symrise
VC Fund
|
2 | United States, Sweden, Denmark | Series A, Seed | Biotechnology, Health Care, Pet | $4.2M–$7.4M |
| Access all 407 investors in Denmark Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 415
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $35M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
- Vantia Therapeutics — Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and representbillion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup's mission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups. BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Seed
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 93
- Round size: Seed $532k–$1.8M; Pre-Seed $530k–$5.2M; Convertible Note $495k–$1.6M
- Lead/follow: 92% lead, 8% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We can accompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 231
- Round size: Seed $830k–$4.9M; Pre-Seed $384k–$2.4M; Venture - Series Unknown $1.2M–$23M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $343M in 2023
Portfolio highlights
- Advalight — Advalight is a young, dynamic company dedicated to providing high-quality laser equipment for dermatological treatments. The company has patented an innovative technology for use in the removal of vascular lesions, acne treatment, skin rejuvenation and many other skin-enhancing procedures. The ground-breaking product was launched the summer 2014.Advalight is based on five years of scientific work in the Physics Department at the Technical University of Denmark. The founders include two PhDs and it is their research that forms the basis of Advalight. The company's main focus is on research and development and with the right external partners we believe that the market for dermatological lasers will be transformed. Advalight is therefore seeking collaboration with external partners with established distribution and sales channels.
- Sigma Estimates — Sigma Estimates was founded in 2003 under the name CodeGroup and is less than ten years been the market leader in software solutions for the calculation.For Sigma Estimates is the main task to develop it, to encourage and improve the work of kalkulationsopgaver in the construction industry. But it must be seen in a larger context, and thereforeSigma also the ultimate tool when the company's work processes more efficient and streamlined.Sigma typically helps companies to reach a best practice to select the projects that are profitable and to foster knowledge sharing within the company.Sigma Estimates are more than any other has come to stand for quality and ease of use. The goal is to bring together IT knowledge with kalkulationsviden and have it all to go up to a higher level.
- Merus Audio — Merus Audio is an audio company that develops switching audio amplifiers. The developed audio amplifiers consist a multilevel audio amplifier technology, which is a combination of a multilevel switching topology and a dynamic power management scheme to improve efficiency and compactness. The company's product eximo MA12040/12040P andMA12070/MA12070P are used for home theater systems, TVs, sound bars, stereo systems, mobile phones, and portable media players. They cut down power losses during operations.Merus Audio was found by Mikkel Hoyerby, and Hans Andersen in 2010; and is headquartered in Herlev, Denmark.
Export and Investment Fund serves as a single point of contact for Danish firms seeking risk-tolerant government finance. serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, United States, Norway
Investor stats
- Total investments: 148
- Round size: Seed $395k–$11M; Pre-Seed $807k–$2.9M; Series A $5.9M–$84M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Cortas — Cortas is a tech-enabled Danish property management company that offers an end-to-end, institutional-grade management service for real estate portfolios. The company replaces traditional, fragmented real estate administration by combining a dedicated team of industry experts with a proprietary digital platform to streamline operations, compliance, and financial reporting.
- Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.
- Rodinia Generation — Rodinia Generation offers environmental clothes manufacturing technologies that helps to eliminate overproduction in the fashion sector.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 2-4 MEUR in rounds of 2-10 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 216
- Round size: Seed $549k–$5.2M; Series A $3.8M–$17M; Venture - Series Unknown $580k–$5.1M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $74M in 2021
Portfolio highlights
- Expanite — Expanite has developed a series of unique solutions for surface-hardening of stainless steel. With the opportunity of processing most common stainless steel alloys - either in-house or at Expanite's treatment centre - the company offers significantly improved corrosion, wear, fatigue and scratch resistance
- Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.
- Reapplix — Reapplix ApS, a research and development company, identifies blood-derived proteins that improve wound healing, isolates them, and reapplies them to patients with chronic wounds. The company was founded in 2008 and is based in Birkerod, Denmark.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 63
- Round size: Series A $5.5M–$61M; Series B $9.5M–$58M; Series C $4.1M–$63M
- Lead/follow: 16% lead, 84% follow
- Last fund: May invest from a new fund soon — raised $92M in 2019
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Denmark, United States, Sweden
Investor stats
- Total investments: 154
- Round size: Seed $506k–$4.6M; Pre-Seed $307k–$2.5M; Venture - Series Unknown $513k–$3.2M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $64M in 2020
Portfolio highlights
- Thiax — ThiaX maps the strain and crystallinity in polymer and composite materials using cutting-edge X-ray diffraction (XRD) technology.
- spektr — Automate KYB, KYC onboarding, risk monitoring, and case management, reducing false positives and manual work for faster, more secure processes.
- Acodyne — Heavy-lift eVTOL cargo UAVs. Heavy payloads, high speed, autonomous flight.
Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$3.4M; Series A $4.7M–$5.9M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Life Science
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Denmark, Sweden
Investor stats
- Total investments: 32
- Round size: Seed $610k–$5.6M; Pre-Seed $880k–$1.9M; Series A $6.8M–$18M
- Lead/follow: 59% lead, 41% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2024
Portfolio highlights
- OlsAro — OlsAro produces salt-tolerant crops.
- MÖ Foods — MÖ Kaurajogu is domestic, completely herbal and above all delicious. All our products are manufactured in Central Ostrobothnia, Lohtaja.
- AquaNab Solutions — AquaNab is a biotechnology startup developing precision immunotherapies for aquaculture. The company's core platform uses alpaca-derived nanoantibodies (called AquaNabs) formulated directly into fish feed. This approach allows the therapeutic molecules to cross the fish's intestinal barrier and target pathogens from the bloodstream.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 131
- Round size: Series A $9.5M–$62M; Series B $14M–$135M; Series C $21M–$80M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely actively investing — fresh fund, raised $296M in 2026
Portfolio highlights
- Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
- GT Medical Technologies — GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes.
- Endovascular Engineering — Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The Footprint Firm is an advisory and investment company with a sole focus on sustainability.
Show more...Investment focus
- Industry: Software, Renewable Energy, Energy Management
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Spain, Norway
Investor stats
- Total investments: 25
- Round size: Seed $2.2M–$5.4M; Pre-Seed $863k–$4M; Series A $4.7M–$18M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $54M in 2024
Portfolio highlights
- Vaja — Vaja is on a mission to accelerate the transition to a net-zero world via disruptive innovations for solar farms.
- Reel Energy — Reel empowers all companies to procure renewable electricity that makes a real difference for the climate.
- Kvasir Technologies — Imagine a world without fossil fuelsThis is where we come in! We have invented a solution that makes this possible already in 2050.
2xN operates as a venture capital firm.
Show more...Investment focus
- Industry: Software, Information Technology, Quantum Computing
- Stage:Seed, Series A, Series B
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 36
- Round size: Seed $1.9M–$6.9M; Series A $6.4M–$63M; Series B $15M–$125M
- Lead/follow: 11% lead, 89% follow
- Last fund: Likely still investing — raised $120M in 2022
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- QSimulate — QSimulate is a simulation platform that solves pressing problems for the chemical and pharmaceutical industries. It aims to deliver best-time-to-solution algorithms to chemical and pharmaceutical industries to accelerate their computational R&D. It is headquartered in Cambridge, Massachusetts.
- Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Health Care, Information Technology, Software
- Stage:Venture - Series Unknown, Series A, Seed
- Geography: United Kingdom, Denmark, Germany
Investor stats
- Total investments: 61
- Round size: Seed $2.6M–$6M; Series A $2M–$15M; Venture - Series Unknown $1.8M–$10M
- Lead/follow: 82% lead, 18% follow
Portfolio highlights
- Silicon MicroGravity — Silicon Microgravity Limited is a spin-out from Cambridge University. The underpinning sensor technology was developed through a collaboration with BP plc and provides a breakthrough in the management of oil and gas reservoirs. The technology has been developed in Cambridge University’s Nanoscience Centre primarily funded by BP and Innovate UK.
- ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
- Formalize — Formalize delivers a cloud-based compliance operations platform designed for governance, risk, and control workflows, enabling businesses to automate processes around frameworks such as NIS2, DORA, ISO 27001, and GDPR. The platform lets users centralize risk and incident tracking, manage third-party audits and controls, and build customizeddashboards and workflows across compliance, supplier management, and governance.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 578
- Round size: Series A $20M–$128M; Series B $27M–$151M; Post-IPO Equity $35M–$275M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $120M in 2025
Portfolio highlights
- Serapha Bio —
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 96
- Round size: Series A $3.5M–$32M; Series B $5.6M–$30M; Venture - Series Unknown $2.1M–$48M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Athian — Funding livestock sustainability via a connected carbon marketplace.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Meala Foodtech — Revolutionary texturized plant proteins that replace eggs and hydrocolloids. Clean-label, allergen-free solutions for baking, savory foods, and dressings.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Biopharma
- Stage:Pre-Seed, Series A, Seed
- Geography: Denmark
Investor stats
- Total investments: 5
- Round size: Series A $5.9M–$20M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
ACME is an early-stage venture firm investing in frontier technologies before they're mainstream. The firm is headquartered in San Francisco, California and invests across the USA and Europe.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Canada
Investor stats
- Total investments: 228
- Round size: Seed $1.6M–$8.6M; Series A $4.4M–$28M; Series B $15M–$65M
- Lead/follow: 21% lead, 79% follow
- Last fund: Likely still investing — raised $10M in 2022
Portfolio highlights
- Treon — Treon is a product company in the business of offering intelligent IOT products and solutions and custom design services for connected devices. Their customer base is global and in multiple industry verticals. They specialize in highly integrated industrial design led products utilising mobile industry technologies where their founders have a verystrong backround in new mobile innovations.
- Stendr — AI-powered air defense consolidating sensors into real-time operational view. Built for modern drone threats. NATO-aligned European sovereignty.
- Plot — We power the best creative teams to help streamline creative development and cross-collaborate in one source of truth.
PINC was launched as Paulig Incubator in 2018 to help Paulig stay in the forefront of relevant innovations, as well as to contribute to a tastier, healthier and more sustainable planet. Today, our ambition is the same, but we have developed into a corporate venture arm. We aim for strategic, financial, and societal impact in our investments, fostering a sustainable food system for tomorrow. We are investing across the agrifood value chain in three primary impact themes: Improve planetary health and diet within the current food system: This includes innovations in agriculture and food security, such as advanced crop breeding or green fertilizers, innovative ingredients and next generation healthy foods, as well as solutions for tracking and improving climate and nature. Novel technologies to feed 10 BN people by 2050: Technologies needed to sustainably produce enough food for our growing population. This includes food production without land use change, such as precision fermentation and cell-culture. A circular system for food & materials: Regardless of whether we grow our food in soil or in bioreactors, the system needs to be circular. Some examples are upcycled ingredients, food from unused sources, new coating and packaging solutions, as well as technologies to prevent or make better use of side streams. We are looking for entrepreneurs in an attractive market space with an intrinsic drive to find a solution to the problem they are addressing, a clear and scalable plan for success, a reliable team and partners whom we can trust and work closely with.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Agriculture
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 24
- Round size: Seed $2.4M–$7M; Pre-Seed $89k–$2.8M; Series A $4.1M–$7.2M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- OlsAro — OlsAro produces salt-tolerant crops.
- Amatera — Amatera is a biotechnology research company that leverages the latest techniques in biotechnology, to create coffee varieties. Amatera urges to make coffee varieties more sustainable and climate resistant to fill that massive demand. Founded by Omar Dekkiche and Lucie Kriegshauser in 2022 and is located in Paris, France.
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, Biotechnology, Medical Device
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 32
- Round size: Seed $1.2M–$9.1M; Series A $1.5M–$23M; Venture - Series Unknown $2.8M–$31M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Rokoko — Rokoko | Affordable high-end motion capture and animation tools for body, hand, and face capture + software with native integrations for all major animation software and game engines
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 13
- Round size: Series A $20M–$73M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — raised $138M in 2021
Portfolio highlights
- ArgusEye — ArgusEye is a biotechnology company that provides sensor solutions for real-time detection of biological systems and processes. ArgusEye's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing with fiber optics. By adding customized receptors, ArgusEye can offer flexible and sensitivesensing systems for a variety of targets.
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
- Hoba Therapeutics — Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures. <br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 283
- Round size: Seed $1.1M–$9.3M; Pre-Seed $850k–$3.5M; Series A $4.5M–$30M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $110M in 2022
Portfolio highlights
- Cygrid — Cygrid turns identity data into quantified risk scores and automated enforcement, delivering predictable risk reduction and measurable ROI. Our solution uses AI agents to continuously assess identity risk and reduce exposure across cloud and SaaS environments. Cygrid covers human, non-human, and AI agent identities, providing unified visibility across the entire identity landscape. We help CISOs, CTOs, CROs, and technical teams uncover hidden attack paths, reduce the identity attack surface, and make the identity space measurable, actionable, and controllable for Enterprises. Cygrid platform makes Identity risk management simple. Our team will be happy to talk to you and see how our solution will help you to manage cyber risks for identities efficient and secured. Cygrid builds a high ownership culture focused on trust, accountability, and results. We work in a flexible hybrid model, encourage direct communication, and expect initiative from every team member. We value integrity, continuous learning, and strong collaboration across product, engineering, and security. Identity Security made easy!
- 42matters — 42matters offers a full suite of mobile and connected TV app intelligence solutions, including APIs, file dumps, and visual, web-based platforms.
- Lightspring — Lightspring is a photonics technology company developing advanced 3D optical interconnection solutions for photonic systems,Its platform enables precise, adaptable connections between chips, fibers, and light sources beyond traditional packaging constraints.This company focuses on scalable photonic integration to accelerate the development of high-performance optical systems.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 86
- Round size: Series A $3.8M–$65M; Series B $17M–$135M; Series C $29M–$83M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $246M in 2020
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Inbiomotion — Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.Inbiomotion's uniquediagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 141
- Round size: Series A $6M–$73M; Series B $12M–$92M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $179M in 2024
Portfolio highlights
- Neobiomics — Neobiomics is a Swedish life-science company that develops nutritional products for preterm infants and neonatal care. Its best-known products include ProPrems® and NeoMega36®.
- AMRA Medical — AMRA Medical is a digital health company transforming medical research and clinical care using rapid whole-body MRI technology.
- Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Nicholas Francis is based out of Copenhagen, Hovedstaden, and is the Founder of Francis Family Funds. Nicholas previously worked at framebunker as a Co-Founder.
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 4
- Round size: Seed $983k–$8.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan creates a water resilience planning platform for managing water availability in facilities. The company employs artificial intelligence to automatically collect operational data from businesses and combine it with local water satellite imagery to provide a real-time financial assessment of water risk and to offer modified mitigation andadaptation options.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 109
- Round size: Seed $2M–$10M; Pre-Seed $450k–$6.3M; Series A $2M–$40M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $222M in 2021
Portfolio highlights
- WOW EARN — Discover WOW EARN, the all-in-one Web3 app with crypto mining, multi-chain wallet, staking NFTs, and marketplace dApps. Join the global Web3 community today.
- EV Biotech — DANU strain engineering creates Precision Biopolymers For High-Performance Applications through strain engineering and AI.
- foodforecast — AI supported solution to reduce food waste.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, Lundbeckfond Ventures invests up to € 50 million. Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 74
- Round size: Series A $10M–$50M; Series B $20M–$95M; Series C $10M–$53M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- SNIPR Biome — We are the CRISPR Microbiome Company; Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
- Women in Life Science Denmark — WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB. The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced. The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companies Karolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Venture - Series Unknown, Seed
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 32
- Round size: Venture - Series Unknown $2.1M–$10M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- BOOST Pharma — BOOST Pharma is developing BT-101, an off-the-shelf therapy for early intervention in children with severe osteogenesis imperfecta (OI).
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
- Umecrine Cognition — Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain.
At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Denmark, Sweden, Finland
Investor stats
- Total investments: 25
- Round size: Seed $1M–$5.5M; Pre-Seed $917k–$1.7M; Venture - Series Unknown $1.1M–$7.5M
- Lead/follow: 60% lead, 40% follow
- Last fund: Likely actively investing — fund raised in 2026
Portfolio highlights
- Velatir — Velatir helps you stay in control of AI decisions. With real-time monitoring, AI risk scoring, we make responsible, transparent AI easy.
- Wilmo AI — AI agents that resolve ecommerce support tickets on autopilot. Automate order tracking, returns, and customer service across every channel.
- Spiich Labs — AI for revenue teams that win on relationships. Spiich preps your meetings, updates your CRM and drafts follow-ups. Reps save 9+ hours every week.
Bioqube Ventures helps science succeed by turning discoveries into transformative medicines.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$24M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Spica Therapeutics — Spica Therapeutics develops precision therapies that selectively target disease-driving macrophage subsets in oncology, fibrosis and chronic diseases.
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Dawn Biopharma is a global investment firm of KKR.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United States, Denmark, France
Investor stats
- Total investments: 14
- Round size: Seed $15M–$32M; Series A $17M–$165M; Series B $115M–$135M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Vedana Therapeutics — Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
- Expedition Therapeutics — Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide. ABOUT US At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $470M in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies. The Fund provides risk capital that enables cutting-edge initiatives to achieve results substantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 98
- Round size: Seed $66k–$2.1M; Grant $38k–$1.1M; Pre-Seed $64k–$1.6M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Prezio — Electricity prices with grid fees, taxes and levies, for every 15 minutes, through one API.
- PerPlant — PerPlant gives tractors the ability to see every plant. AI-powered cameras that cut input costs by 50% on average.
- Tailwind Biotech — AI-powered synthetic DNA design services for improved strain development. We use Artificial Intelligence to help biotech companies achieve more effective and more efficient bioproduction processes. Our technology designs best-in-class synthetic DNA Promoters and Terminators, and performs gene codon optimizations that help to maximise biomanufacturing yields while reducing development costs.
WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Pre-Seed
- Geography: United States, France, Denmark
Investor stats
- Total investments: 22
- Round size: Seed $3.4M–$20M; Series A $6.8M–$48M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
- Switch Bioworks — Switch Bioworks engineers symbiotic microbes to produce sustainable nitrogen fertilizer under the control of precise genetic circuits.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Farming
- Stage:Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 6
- Round size: Seed $4.3M–$8.8M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 360
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- IMIO — Improve efficiency across the crop nutrient cycle. IMIO natural microbial products reliably increase nutrient availability and reduce tillage.
- DMC Biotechnologies — Transforming How the World Makes Chemicals
Unconventional Ventures invests in startups in the pre-seed and seed stage led by diverse founders identifying as women, people of color, immigrants and/or LGBTQ+, building scalable impact tech companies in the Nordics and beyond.
Show more...Investment focus
- Industry: Health Care, Software, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 21
- Round size: Seed $1M–$5.2M; Pre-Seed $1.5M–$2.8M; Series A $4.7M–$18M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $31M in 2022
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Boldr — Sustainability meets design. Save money and live more sustainably with Boldr products.
- Pixel Systems — Pixel Systems is a AI technology company developing advanced digital content verification solutions. Its platform detects AI-generated and manipulated images, videos, and documents to help businesses prevent fraud and verify authenticity. The company provides API-based and dashboard solutions for insurance, financial services, compliance, and digital platforms.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in various sectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 851
- Round size: Seed $680k–$6.5M; Series A $3M–$31M; Venture - Series Unknown $911k–$12M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $515M in 2022
Portfolio highlights
- Extoll — EXTOLL, a leader in high-speed, ultra-low power SerDes and Chiplet connectivity, offers semiconductor IP with the smallest footprints and highest PPA. Serving global ASIC, SoC, and Chiplet markets, our portfolio includes tailored NoC (Network-on-Chip) and Die-to-Die solutions. EXTOLL drives innovation, enabling successful migration into the Chiplet Age.
- Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
- BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 192
- Round size: Series A $3.7M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Arch Oncology — Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
- Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation
- AGTC — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 124
- Round size: Grant $1.6M–$10M; Series C $10M–$127M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Wysa — Use Wysa to vent or just talk through negative thoughts and emotions. Let it help you cope with pandemic anxiety and lockdowns. It is anonymous, safe and free.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
Steen Riisgaard
Show more...Investment focus
- Industry: Life Science, Therapeutics, Biotechnology
- Stage:Pre-Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 171
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Switzerland, Denmark
Investor stats
- Total investments: 58
- Lead/follow: no public data
Portfolio highlights
- Vandria — At the vanguard of Mitochondrial research
- Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series C
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 19
- Round size: Series B $5.6M–$30M; Series C $5.5M–$15M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Silecs — PiBond is an independent European maker of ultra-pure patterning, dielectric and optical materials for semiconductor, photonics and medical device clients.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Action Pharma — Providing a surprisingly human shopping experience. Trusted and secure. Millions of domains to choose from.
Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.
Show more...Investment focus
- Industry: Cannabis, Health Care, Biotechnology
- Stage:Post-IPO Equity, Seed, Pre-Seed
- Geography: Canada, United States, Denmark
Investor stats
- Total investments: 8
- Round size: Seed $1.8M–$5M; Post-IPO Equity $40k–$53M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- SynBiotic — SYNBIOTIC SE is a leading European corporate group operating in the dynamic environment of the industrial hemp and cannabis market.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Martello Technologies — Prioritize and resolve performance problems and optimize the Microsoft 365 and Teams user experience with Martello Vantage DX.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 285
- Round size: Seed $1.4M–$11M; Series A $2.3M–$18M; Series B $4.2M–$45M
- Lead/follow: 13% lead, 87% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Axelera AI — Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
- Atana Elements — Atana is a data-driven resource company that accelerates the exploration and development of flowing critical minerals.
Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.
Show more...Investment focus
- Industry: Chemical, Biotechnology, Food and Beverage
- Stage:Seed, Pre-Seed
- Geography: Italy, Denmark
Investor stats
- Total investments: 3
- Round size: Seed $4.9M–$7.6M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Dreamfarm — We are a team of food-lovers 100% made in Italy! We dreamt of a better, tastier, more sustainable future and decided to join forces to create something special.
Northzone is a multi-stage venture capital firm operating across Europe and the US. Since 1996, it has backed more than 250 companies, including Spotify, Klarna, Spring Health, and Black Forest Labs.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, FinTech
- Stage:Series A, Series B, Seed
- Geography: United States, Sweden, United Kingdom
Investor stats
- Total investments: 375
- Round size: Seed $2.4M–$23M; Series A $4.5M–$32M; Series B $7.4M–$100M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- Duvo — Duvo brings your people, AI agents and existing systems together to map, run and improve your processes, with decisions, exceptions and results in one place.
- Rayon — Built for Speed. Designed for Teams.
- SolveAI —
Targeting critical European re-industrialisation technology across pioneering hardware sectors with capital efficient growth investments.
Show more...Investment focus
- Industry: Energy, Energy Storage, Renewable Energy
- Stage:Venture - Series Unknown, Seed
- Geography: Denmark, Germany, Sweden
Investor stats
- Total investments: 29
- Round size: Seed $3M–$8.7M; Venture - Series Unknown $4.5M–$9.8M
- Lead/follow: 72% lead, 28% follow
- Last fund: Likely still investing — raised $286M in 2024
Portfolio highlights
- Stabl Energy — Scalable battery storage systems for energy storage in industry and commerce made by STABL Energy help to utilise the full potential of renewable energies.
- Green Hydrogen Systems — GreenHydrogen believes that electrolysers have a great potential to become a core technology in green and renewable energy.
- Hybrid Greentech — Hybrid Greentech offers end-to-end profitable solutions for BESS projects, from detailed business case and sizing analysis to project development services, EPC management, and operations and optimization for multi-market revenue stacking.
We invest in disruptive and encouraging Agri-Food tech and Food Loss companies, reshaping our food systems in order to solve the current & future problems of production.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Yeastup — Yeastup transforms brewer's yeast into proteins & fibers for food & supplements. Contact us for sustainable ingredient solutions.
- New School Foods — Salmon, made from plants. Clean label with ALL the Omega-3s, NONE of the mercury. Made in Canada.
About 30,000 products - 6,000 customers in roughly 160 countries. First synthesis of vanillin in 1874.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pet
- Stage:Series A, Seed
- Geography: United States, Sweden, Denmark
Investor stats
- Total investments: 6
- Round size: Series A $4.2M–$7.4M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Indevex AB — Indevex is a science-based and privately owned biotech company from Sweden. A natural and reliable partner, providing evidence based natural nutrition concepts based on the patented NGC™ Formula.
- Bond Pet Foods — We make vegan and protein-rich pet food and treats formulated by board-certified veterinary nutritionists.
Biotech Investor funding in Denmark at a glance
Stats across 460 deals from 407 investors.
Access all 407 investors in Denmark Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 407 investors investing in Denmark Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!